Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China...
PLBIO: The net profit for the third quarter was 121 million yuan, a decrease of 43.74%
Open Source Securities: API companies accelerate the layout of innovative drugs, and the AI + medical layout is gradually deepening
PLBIO released its performance for the first half of the year, with a net profit attributable to the parent company of 236 million yuan, a decrease of 27.89%
The Mystery of BTBP "Refusing" PLBIO
BTBP plans to abandon the acquisition of PLBIO business opportunity
The biopharmaceutical sector saw a short-term surge, with BTBP hitting the daily limit